Kater AP, van Oers MH, van Norden Y, van der Straten L, Driessen J, Posthuma WF, Schipperus M, Chamuleau ME, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EW, Raymakers RA, Schaafsma MR, Dobber JA, Kersting S, Levin M-D. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica 2018; 104(1):147-154; https://doi.org/10.3324/haematol.2018.193854.